Knowing how critical time and resources are in the drug discovery process, we are proud to announce our new COVID-19 Playbook, which helps surface critical market intelligence and trends surrounding potential treatments for COVID-19. Provided at no cost to researchers, the COVID-19 Playbook will help monitor vaccines that are in development for COVID-19 and other strains of coronavirus; monitor trending drugs that are being tested for COVID-19; and assess which drugs are being repurposed to help treat infected people.
The COVID-19 Playbook is a front-end user interface of our advanced analytics platform, powered by patented Natural Language Processing (NLP) techniques and taxonomies developed by domain experts with years of academic and pharmaceutical industry experience. It connects data from a wide range of sources including clinical trials, research papers, business events, announcements, media coverage, drug developments and more. Context is extracted from the various data types and visualizations and actionable insights are generated.
Actionable Insights Accelerate Drug Discovery
Like Signals Analytics’ other playbooks, the COVID-19 Playbook is aimed at heads of research, development, and innovation as well as leaders responsible for growth, business development, mergers and acquisitions, looking for ways to speed up the vaccine and drug discovery process. The aggregated dashboards such as such the Drug Pipeline Overview, COVID-19 Target and Modality Landscape, and Research Paper Assessment, address many important business questions such as: what are the leading and emerging targets being analyzed for COVID-19, which are the leading and emerging drugs and vaccines that are being researched and tested, which drugs are being repurposed to treat COVID-19, and which entities are leading and emerging for COVID-19 testing and treatment. In addition, users can set manual alerts through the Findings section to receive updates once a week.
Advanced Analytics Surface Trends
“As the COVID-19 pandemic progresses, a deluge of data is being generated every day and it is impossible for researchers to keep up,” said Gil Sadeh, CEO of Signals Analytics. “Most other platforms provide insights based on limited data sets or simple reference listings that require the user to input specific search parameters. The Signals Analytics platform on the other hand is designed to surface trends and actionable insights across a wide range of data sets to alleviate the burden researchers and analysts face as they look for clues that will speed up vaccine development and identify effective treatments. In the middle of this pandemic, every minute counts. We are proud to offer our COVID-19 Playbook to industry leaders, non-profits and government agencies to turn a very labor-intensive process filled with risk and uncertainty into something actionable and relevant that will speed up the end to this scourge.”
To unlock free access to the COVID-19 Playbook and learn more about how advanced analytics can help in the race to a vaccine and other treatment drugs for COVID-19, fill out our registration form.